Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.56
BGMD's Cash to Debt is ranked higher than
65% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. BGMD: 1.56 )
BGMD' s 10-Year Cash to Debt Range
Min: 0.68   Max: No Debt
Current: 1.56

Equity to Asset 0.22
BGMD's Equity to Asset is ranked higher than
52% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. BGMD: 0.22 )
BGMD' s 10-Year Equity to Asset Range
Min: -12.54   Max: 0.88
Current: 0.22

-12.54
0.88
F-Score: 4
Z-Score: -31.11
M-Score: -1.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -230.99
BGMD's Operating margin (%) is ranked higher than
54% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. BGMD: -230.99 )
BGMD' s 10-Year Operating margin (%) Range
Min: -1783.39   Max: -69.34
Current: -230.99

-1783.39
-69.34
Net-margin (%) -256.65
BGMD's Net-margin (%) is ranked higher than
54% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BGMD: -256.65 )
BGMD' s 10-Year Net-margin (%) Range
Min: -2095.48   Max: -78.43
Current: -256.65

-2095.48
-78.43
ROE (%) -2020.48
BGMD's ROE (%) is ranked lower than
56% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. BGMD: -2020.48 )
BGMD' s 10-Year ROE (%) Range
Min: -224.23   Max: -224.23
Current: -2020.48

ROA (%) -90.61
BGMD's ROA (%) is ranked higher than
51% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. BGMD: -90.61 )
BGMD' s 10-Year ROA (%) Range
Min: -174.66   Max: -67.46
Current: -90.61

-174.66
-67.46
ROC (Joel Greenblatt) (%) -4606.13
BGMD's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. BGMD: -4606.13 )
BGMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9127.71   Max: -327.37
Current: -4606.13

-9127.71
-327.37
Revenue Growth (3Y)(%) -18.80
BGMD's Revenue Growth (3Y)(%) is ranked higher than
60% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BGMD: -18.80 )
BGMD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -18.8
Current: -18.8

EBITDA Growth (3Y)(%) -51.80
BGMD's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BGMD: -51.80 )
BGMD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -40.2
Current: -51.8

EPS Growth (3Y)(%) -54.40
BGMD's EPS Growth (3Y)(%) is ranked higher than
53% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. BGMD: -54.40 )
BGMD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -41.3
Current: -54.4

» BGMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BGMD Guru Trades in Q4 2013

Paul Tudor Jones 27,645 sh (New)
» More
Q1 2014

BGMD Guru Trades in Q1 2014

Paul Tudor Jones 11,879 sh (-57.03%)
» More
Q2 2014

BGMD Guru Trades in Q2 2014

Paul Tudor Jones 11,879 sh (unchged)
» More
Q3 2014

BGMD Guru Trades in Q3 2014

Paul Tudor Jones 11,779 sh (-0.84%)
» More
» Details

Insider Trades

Latest Guru Trades with BGMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.60
BGMD's P/B is ranked higher than
65% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. BGMD: 6.60 )
BGMD' s 10-Year P/B Range
Min: 2.56   Max: 141.5
Current: 6.6

2.56
141.5
P/S 3.00
BGMD's P/S is ranked higher than
74% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. BGMD: 3.00 )
BGMD' s 10-Year P/S Range
Min: 2.73   Max: 121
Current: 3

2.73
121
EV-to-EBIT -1.17
BGMD's EV-to-EBIT is ranked higher than
67% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BGMD: -1.17 )
BGMD' s 10-Year EV-to-EBIT Range
Min: -9.1   Max: -0.6
Current: -1.17

-9.1
-0.6
Current Ratio 1.24
BGMD's Current Ratio is ranked higher than
53% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BGMD: 1.24 )
BGMD' s 10-Year Current Ratio Range
Min: 0.3   Max: 7.97
Current: 1.24

0.3
7.97
Quick Ratio 1.18
BGMD's Quick Ratio is ranked higher than
56% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. BGMD: 1.18 )
BGMD' s 10-Year Quick Ratio Range
Min: 0.3   Max: 7.96
Current: 1.18

0.3
7.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 33.00
BGMD's Price/Net Cash is ranked higher than
84% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BGMD: 33.00 )
BGMD' s 10-Year Price/Net Cash Range
Min: 3.14   Max: 368
Current: 33

3.14
368
Price/Net Current Asset Value 16.50
BGMD's Price/Net Current Asset Value is ranked higher than
83% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BGMD: 16.50 )
BGMD' s 10-Year Price/Net Current Asset Value Range
Min: 3.11   Max: 184
Current: 16.5

3.11
184
Price/Tangible Book 8.25
BGMD's Price/Tangible Book is ranked higher than
70% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. BGMD: 8.25 )
BGMD' s 10-Year Price/Tangible Book Range
Min: 2.84   Max: 92
Current: 8.25

2.84
92
Price/Median PS Value 0.20
BGMD's Price/Median PS Value is ranked higher than
99% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. BGMD: 0.20 )
BGMD' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 7.89
Current: 0.2

0.33
7.89
Earnings Yield (Greenblatt) -85.50
BGMD's Earnings Yield (Greenblatt) is ranked lower than
53% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. BGMD: -85.50 )
BGMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -85.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:RBM.Germany,
BG Medicine is a life sciences company engaged into discovery, development, and commercialization of novel diagnostic tests based on biomarkers. Its tests include BGM Galectin-3, CardioSCORE.
» More Articles for BGMD

Headlines

Articles On GuruFocus.com
comment on BGMD Jun 09 2011 

More From Other Websites
Most active Nasdaq-traded stocks Dec 19 2014
Nasdaq stocks posting largest volume increases Dec 18 2014
BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Nov 26 2014
BG MEDICINE, INC. Financials Nov 22 2014
BG Medicine, Inc. Welcomes Presentation of Clinical Data on Galectin-3 Testing at the American Heart... Nov 21 2014
BG Medicine, Inc. Welcomes Presentation of Clinical Data on Galectin-3 Testing at the American Heart... Nov 20 2014
10-Q for BG Medicine, Inc. Nov 16 2014
BG MEDICINE, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2014
Q3 2014 BG Medicine Inc Earnings Release - Before Market Open Nov 13 2014
BG Medicine Reports Third Quarter 2014 Financial Results Nov 13 2014
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Nov 13 2014
BG Medicine Reports Third Quarter 2014 Financial Results Nov 13 2014
BG Medicine Announces Q3 2014 Financial Results Release Date and Conference Call Information Nov 07 2014
BG Medicine Announces Q3 2014 Financial Results Release Date and Conference Call Information Nov 07 2014
BG MEDICINE, INC. Files SEC form 8-K, Other Events Oct 17 2014
BG MEDICINE, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Notice of... Sep 11 2014
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 14 2014
BG MEDICINE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 05 2014
5 Stocks Under $10 Set to Soar May 29 2014
Covance Expands in Market Access May 20 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK